Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017110830) METHOD FOR PREDICTING EFFECT OF COMBINATION THERAPY ON CANCER USING L-ASPARAGINASE AGENT AND AUTOPHAGY INHIBITOR, AND CANCER THERAPEUTIC AGENT
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/110830 International Application No.: PCT/JP2016/087989
Publication Date: 29.06.2017 International Filing Date: 20.12.2016
IPC:
C12Q 1/68 (2006.01) ,A61K 31/351 (2006.01) ,A61K 31/47 (2006.01) ,A61K 31/52 (2006.01) ,A61K 31/5377 (2006.01) ,A61K 38/43 (2006.01) ,A61K 45/00 (2006.01) ,A61P 15/00 (2006.01) ,A61P 35/00 (2006.01) ,A61P 35/02 (2006.01) ,A61P 43/00 (2006.01) ,C12N 15/00 (2006.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
Q
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1
Measuring or testing processes involving enzymes or micro-organisms; Compositions therefor; Processes of preparing such compositions
68
involving nucleic acids
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
335
having oxygen as the only ring hetero atom, e.g. fungichromin
35
having six-membered rings with one oxygen as the only ring hetero atom
351
not condensed with another ring
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
47
Quinolines; Isoquinolines
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519
ortho- or peri-condensed with heterocyclic rings
52
Purines, e.g. adenine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
535
having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
5375
1,4-Oxazines, e.g. morpholine
5377
not condensed and containing further heterocyclic rings, e.g. timolol
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
43
Enzymes; Proenzymes; Derivatives thereof
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
15
Drugs for genital or sexual disorders; Contraceptives
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
02
specific for leukemia
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43
Drugs for specific purposes, not provided for in groups A61P1/-A61P41/108
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
Applicants:
国立大学法人東京医科歯科大学 NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY [JP/JP]; 東京都文京区湯島一丁目5番45号 5-45, Yushima 1-chome, Bunkyo-ku, Tokyo 1138510, JP
Inventors:
高橋 寛吉 TAKAHASHI, Hiroyoshi; JP
井上 純 INOUE, Jun; JP
稲澤 譲治 INAZAWA, Johji; JP
Agent:
志村 光春 SHIMURA Mitsuharu; JP
Priority Data:
2015-25011222.12.2015JP
Title (EN) METHOD FOR PREDICTING EFFECT OF COMBINATION THERAPY ON CANCER USING L-ASPARAGINASE AGENT AND AUTOPHAGY INHIBITOR, AND CANCER THERAPEUTIC AGENT
(FR) PROCÉDÉ DE PRÉDICTION DE L'EFFET D'UNE POLYTHÉRAPIE SUR UN CANCER UTILISANT UN AGENT L-ASPARAGINASE ET UN INHIBITEUR D'AUTOPHAGIE, ET AGENT THÉRAPEUTIQUE ANTICANCÉREUX
(JA) がんに対するL-アスパラギナーゼ剤とオートファジー阻害剤の併用療法の効果の予測方法、及び、がん治療剤
Abstract:
(EN) The present invention addresses the problem of finding an index of whether or not a combination therapy using L-asparaginase and an autophagy inhibitor is effective, and providing a cancer therapeutic agent for which the index can be used, and provides: a method for obtaining data on prediction of the effect of a pharmaceutical agent, wherein, when the functional deletion of p53 due to gene mutation is identified in a cancer specimen, the data is determined to be negative in terms of the effect of a combination therapy using L-asparaginase and an autophagy inhibitor on cancer; and a therapeutic agent which is for a cancer showing resistance to sole administration of an L-asparaginase agent, and which is characterized by containing L-asparaginase and an autophagy inhibitor.
(FR) La présente invention résout le problème d'identification d'un indice de l'efficacité ou non d'une polythérapie utilisant une L-asparaginase et d'un inhibiteur d'autophagie, et la préparation d'un agent thérapeutique anticancéreux pour lequel l'indice peut être utilisé, et décrit : un procédé d'obtention de données de prédiction de l'effet d'un agent pharmaceutique, selon lequel, lorsque la délétion fonctionnelle de p53 due à une mutation de gène est identifiée dans un prélèvement cancéreux, les données sont déterminées comme étant négatives en termes d'effet d'une polythérapie utilisant la L-asparaginase et un inhibiteur d'autophagie sur le cancer; et un agent thérapeutique qui est destiné à un cancer présentant une résistance à la seule administration d'un agent L-asparaginase, et qui est caractérisé en ce qu'il contient de la L-asparaginase et un inhibiteur d'autophagie.
(JA) 本発明は、L-アスパラギナーゼとオートファジー阻害薬の併用療法が奏功するか否かの指標を見出し、かつ、当該指標を活用し得るがん治療剤を提供することを課題し、がん検体における遺伝子変異によるp53の機能欠失を認めた場合に、当該がんにおけるL-アスパラギナーゼ、及び、オートファジー阻害剤の併用療法の効果の否定的データとする薬剤の効果の予測データの取得方法、及び、L-アスパラギナーゼ、及び、オートファジー阻害剤を含有することを特徴とする、L-アスパラギナーゼの剤の単独投与に対して抵抗性を有するがんの治療剤、を提供する。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)